Antithrombin III deficiency – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:28:35 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Antithrombin III deficiency – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness of Atenativ for Patients with Congenital Antithrombin Deficiency Undergoing Surgery or Childbirth https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-atenativ-for-patients-with-congenital-antithrombin-deficiency-undergoing-surgery-or-childbirth/ Wed, 29 Apr 2026 14:23:15 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-atenativ-for-patients-with-congenital-antithrombin-deficiency-undergoing-surgery-or-childbirth/ This clinical trial is focused on studying the effectiveness and safety of a treatment called Atenativ in patients with a condition known as congenital antithrombin deficiency. This condition is a rare genetic disorder where the body does not produce enough of a protein called antithrombin, which helps prevent blood clots. The study aims to understand how well Atenativ works in preventing blood clots in patients with this deficiency who are undergoing surgery or childbirth.

The treatment being tested, Atenativ, is a solution that is given through an intravenous infusion, which means it is administered directly into the bloodstream through a vein. The study will observe patients over a period of time to see if Atenativ can effectively reduce the risk of blood clots during and after surgical procedures or delivery. The study will also monitor the safety of the treatment by checking for any side effects or adverse reactions.

Participants in the study will receive Atenativ and will be closely monitored by healthcare professionals. The study will track the occurrence of any blood clotting events and assess various health parameters to ensure the treatment is safe and effective. The goal is to gather information that could help improve the management of congenital antithrombin deficiency in patients undergoing surgery or childbirth.

]]>